Search - tctmd.com

Displaying 121 - 140 of 240

Sort: Relevancy | Date

Presentation TCT 2013

Genetic Testing is of Clear Clinical Utility in Selected Patients

Presenter: Jessica Mega

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Presenter: Dimitrios Alexopoulos

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Presenter: Freek Verheugt

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Presenter: Pascal Vranckx

October 31, 2013

Presentation TCT 2013

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

Presenter: Michael Ezekowitz

October 31, 2013

Presentation TCT 2013

DES Implantation in a Patient with Atrial Fibrillation

Presenter: Roxana Mehran

October 31, 2013

Presentation TCT 2013

Critical Appraisal and Clinical Implications(3)

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

Clopidogrel Is Cheap, Effective, and Sufficient for Most!

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Presenter: Philippe Gabriel Steg

October 31, 2013

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Presentation TCT 2013

Cangrelor Properties: PK, PD and More

Presenter: Sergio Leonardi

October 31, 2013

Presentation TCT 2013

BRIDGE Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Presentation TCT 2013

A Patient with a Recent Stent Who is Bleeding

Presenter: Peter Wenaweser

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin vs. Heparin ± Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI...

Presenter: Philippe Gabriel Steg

October 30, 2013

Presentation TCT 2013

EUROMAX: Critical Appraisal and Clinical Implications

Presenter: Gregg Stone

October 30, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

Presentation TCT 2013

TCT-9. Racial Disparity With On-Treatment Platelet Reactivity In Patients Undergoing Percutaneous Coronary Intervention

Presenter: Iakshmana Pendyala

October 29, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Advertisement

Genetic Testing is of Clear Clinical Utility in Selected Patients

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

DES Implantation in a Patient with Atrial Fibrillation

Critical Appraisal and Clinical Implications(3)

Clopidogrel Is Cheap, Effective, and Sufficient for Most!

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Cangrelor Will Be the Answer for Most in the Acute Setting!

Cangrelor Properties: PK, PD and More

BRIDGE Recap

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

A Patient with a Recent Stent Who is Bleeding

Featured Trial of the Day: EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin vs. Heparin ± Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI...

EUROMAX: Critical Appraisal and Clinical Implications

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

TCT-9. Racial Disparity With On-Treatment Platelet Reactivity In Patients Undergoing Percutaneous Coronary Intervention

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content